<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03942549</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00019197</org_study_id>
    <nct_id>NCT03942549</nct_id>
  </id_info>
  <brief_title>Changes in the Bladder Micro-environment Following Midurethral Sling Surgery for Stress Urinary Incontinence</brief_title>
  <official_title>Changes in the Bladder Micro-environment Following Midurethral Sling Surgery for Stress Urinary Incontinence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Collins Medical Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This observational cohort study is aimed at determining changes in the cytokine expression
      profile as well as the urinary and vaginal microbiome of women undergoing midurethral sling
      placement for the treatment of stress urinary incontinence.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objectives:

      This is a pilot study to evaluate how midurethral sling (MUS) placement for the treatment of
      stress urinary incontinence (SUI) affects the bladder microenvironment, specifically the
      local microbial community or &quot;microbiome&quot; of the bladder and the cytokine expression profile.
      The investigators also aim to correlate any changes in the microbiome or cytokine expression
      profile with patient-reported urinary symptoms preoperatively and postoperatively.

      Specific Aim 1: Assess the change in the urinary and vaginal microbiome (preoperatively to
      postoperatively) in women undergoing MUS placement for the treatment of SUI. The
      investigators hypothesize that the bladder environment will be disturbed by surgery involving
      the lower urinary tract and will show demonstrable changes in the urinary and vaginal
      microbiota.

      Specific Aim 2: Characterize the cytokine profile of the bladder (preoperatively to
      postoperatively) in women undergoing MUS placement for the treatment of SUI. The
      investigators hypothesize that MUS treatment will change the cytokine profile of the bladder
      and lead to alterations in the expression of pro-inflammatory cytokines.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 3, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 17, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>6 Weeks</target_duration>
  <primary_outcome>
    <measure>Urinary Microbiome</measure>
    <time_frame>Six weeks</time_frame>
    <description>change in the relative abundance of urinary lactobacillus between baseline, 2 and 6 weeks postoperative</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cytokine Profile</measure>
    <time_frame>Six weeks</time_frame>
    <description>Change in cytokine expression profile of the bladder between baseline, 2, and 6 weeks postoperative</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prevalence of overactive bladder symptoms</measure>
    <time_frame>Six weeks</time_frame>
    <description>Validated symptom questionnaires will be collected at baseline and again at 2 and six weeks postoperatively to assess common symptoms associated with overactive bladder.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Stress Urinary Incontinence</condition>
  <arm_group>
    <arm_group_label>MUS Cohort</arm_group_label>
    <description>This cohort will undergo midurethral sling placement.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Retropubic midurethral sling</intervention_name>
    <description>Midurethral sling</description>
    <arm_group_label>MUS Cohort</arm_group_label>
    <other_name>TVT</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will include women over the age of 18 planning to undergo stand-alone
        midurethral sling placement for treatment of stress urinary incontinence.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years old

          -  Planning to undergo retropubic midurethral sling placement

        Exclusion Criteria:

          -  Prior surgery for stress urinary incontinence

          -  Untreated pelvic organ prolapse &gt; Stage II based on POP-Q assessment

          -  Concomitant surgery for prolapse

          -  Current use of anticholinergic medications

          -  Use of systemic or vaginal antibiotics in the last 2 months

          -  Active urinary tract infection

          -  History of recurrent UTI

          -  Pregnancy

          -  History of pelvic radiation or bladder cancer
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ian Fields, MD</last_name>
    <phone>503-494-9855</phone>
    <email>fieldsia@ohsu.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Legacy Good Samaritan Hospital</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Blake Osmundsen, MD</last_name>
      <phone>503-413-5787</phone>
      <email>bosmunds@lhs.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ian Fields, MD</last_name>
      <phone>503-494-9855</phone>
    </contact>
    <investigator>
      <last_name>William T Gregory, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sharon R Edwards, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 3, 2019</study_first_submitted>
  <study_first_submitted_qc>May 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2019</study_first_posted>
  <last_update_submitted>May 6, 2019</last_update_submitted>
  <last_update_submitted_qc>May 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>Ian Fields</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>microbiome</keyword>
  <keyword>cytokine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Enuresis</mesh_term>
    <mesh_term>Urinary Incontinence, Stress</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

